CY1119646T1 - Προφαρμακο αμινοξεος που περιεχει φθοριο - Google Patents

Προφαρμακο αμινοξεος που περιεχει φθοριο

Info

Publication number
CY1119646T1
CY1119646T1 CY20171101062T CY171101062T CY1119646T1 CY 1119646 T1 CY1119646 T1 CY 1119646T1 CY 20171101062 T CY20171101062 T CY 20171101062T CY 171101062 T CY171101062 T CY 171101062T CY 1119646 T1 CY1119646 T1 CY 1119646T1
Authority
CY
Cyprus
Prior art keywords
disorders
amino acid
group
prodrug
huntington
Prior art date
Application number
CY20171101062T
Other languages
English (en)
Inventor
Takashi Hashihayata
Norikazu Otake
Naoki Miyakoshi
Kazunari Sakagami
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of CY1119646T1 publication Critical patent/CY1119646T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχεται προφάρμακο αμινοξέος που περιέχει φθόριο που αντιπροσωπεύεται από τον γενικό τύπο (I) που μετατρέπει ένα αμινοξύ που περιέχει φθόριο το οποίο είναι ένας αγωνιστής μεταβολοτρόπου υποδοχέα γλουταμινικού οξέος της ομάδας 2 σε προφάρμακο, ή φαρμακευτικώς αποδεκτό άλας αυτού. Ειδικότερα, παρέχεται προφάρμακο που αυξάνει την in vivo έκθεση και ενισχύει την απορροφητικότητα από το στόμα και οποιαδήποτε άλλη απορροφητικότητα βλεννογόνου μιας μητρικής ένωσης που δρα στους μεταβολοτρόπους υποδοχείς γλουταμινικού οξέος της ομάδας 2 ως παράγοντας για τη θεραπεία ή πρόληψη ασθενειών στις οποίες λέγεται ότι εμπλέκονται μεταβολοτρόποι υποδοχείς γλουταμινικού οξέος της ομάδας 2, όπως σχιζοφρένεια, αγχώδη διαταραχή και σχετικές ασθένειες, κατάθλιψη, διπολική διαταραχή, επιληψία, αναπτυξιακές διαταραχές, διαταραχές του ύπνου και άλλες νευροψυχιατρικές ασθένειες και εξάρτηση από φάρμακα, γνωστικές διαταραχές, νόσο του Alzheimer, χορεία του Huntington, νόσο του Parkinson, διαταραχές κινητικότητας που σχετίζονται με μυϊκή ακαμψία, εγκεφαλική ισχαιμία, εγκεφαλική ανεπάρκεια, διαταραχές του νωτιαίου μυελού, κεφαλοπάθεια και άλλες νευρολογικές παθήσεις.
CY20171101062T 2012-06-01 2017-10-11 Προφαρμακο αμινοξεος που περιεχει φθοριο CY1119646T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012126162 2012-06-01
JP2013052574 2013-03-15
PCT/JP2013/065202 WO2013180271A1 (ja) 2012-06-01 2013-05-31 含フッ素アミノ酸のプロドラッグ

Publications (1)

Publication Number Publication Date
CY1119646T1 true CY1119646T1 (el) 2018-04-04

Family

ID=49673454

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101062T CY1119646T1 (el) 2012-06-01 2017-10-11 Προφαρμακο αμινοξεος που περιεχει φθοριο

Country Status (32)

Country Link
US (1) US9428483B2 (el)
EP (1) EP2857385B1 (el)
JP (1) JP5979230B2 (el)
KR (1) KR102062936B1 (el)
CN (1) CN104334524B (el)
AU (1) AU2013268303B2 (el)
BR (1) BR112014029478B1 (el)
CA (1) CA2875080C (el)
CY (1) CY1119646T1 (el)
DK (1) DK2857385T3 (el)
ES (1) ES2637986T3 (el)
HK (1) HK1202526A1 (el)
HR (1) HRP20171373T1 (el)
HU (1) HUE034513T2 (el)
IL (1) IL235897B (el)
IN (1) IN2014DN10538A (el)
LT (1) LT2857385T (el)
ME (1) ME02833B (el)
MX (1) MX355161B (el)
MY (1) MY169069A (el)
NO (1) NO2857385T3 (el)
NZ (1) NZ702237A (el)
PH (1) PH12014502670B1 (el)
PL (1) PL2857385T3 (el)
PT (1) PT2857385T (el)
RS (1) RS56328B1 (el)
RU (1) RU2639868C1 (el)
SG (1) SG11201407973SA (el)
SI (1) SI2857385T1 (el)
TW (1) TWI602801B (el)
WO (1) WO2013180271A1 (el)
ZA (1) ZA201408857B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
JP5983714B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
MX2016008110A (es) * 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CN113150030A (zh) * 2015-05-15 2021-07-23 莱克斯特生物技术公司 氧杂二环庚烷前药
HUE056046T2 (hu) 2016-04-18 2022-01-28 Taisho Pharmaceutical Co Ltd Aminosav-származék prodrogja
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038839A1 (fr) 1998-01-28 1999-08-05 Taisho Pharmaceutical Co., Ltd. Derives d'acides amines renfermant du fluor
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
PT1142860E (pt) 1998-12-18 2004-11-30 Taisho Pharmaceutical Co Ltd Intermediarios e processo para a producao de um composto de amino acidos contendo fluor, e uso dos mesmos
JP4783967B2 (ja) 1999-07-21 2011-09-28 大正製薬株式会社 含フッ素アミノ酸誘導体を有効成分とする医薬
BR0215462A (pt) * 2001-12-27 2004-11-30 Taisho Pharmaceutical Co Ltd Derivados de 6-fluorobiciclo[3.1.0]hexano
NZ564692A (en) 2002-06-11 2009-05-31 Lilly Co Eli Prodrugs of excitatory amino acids
CN101362793A (zh) 2002-06-11 2009-02-11 伊莱利利公司 兴奋性氨基酸前药
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
JP5983714B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸プロドラッグの結晶形とその製造方法

Also Published As

Publication number Publication date
MY169069A (en) 2019-02-12
IL235897B (en) 2019-09-26
CN104334524B (zh) 2016-10-12
JPWO2013180271A1 (ja) 2016-01-21
NZ702237A (en) 2016-08-26
IL235897A0 (en) 2015-02-01
SG11201407973SA (en) 2015-01-29
ME02833B (me) 2018-01-20
KR102062936B1 (ko) 2020-01-06
MX355161B (es) 2018-04-06
RU2639868C1 (ru) 2017-12-25
CN104334524A (zh) 2015-02-04
HUE034513T2 (en) 2018-02-28
ZA201408857B (en) 2016-08-31
BR112014029478A8 (pt) 2021-03-16
PH12014502670A1 (en) 2015-02-02
AU2013268303A1 (en) 2014-12-18
US9428483B2 (en) 2016-08-30
BR112014029478A2 (pt) 2017-06-27
HK1202526A1 (en) 2015-10-02
EP2857385B1 (en) 2017-08-02
PL2857385T3 (pl) 2018-01-31
ES2637986T3 (es) 2017-10-18
CA2875080C (en) 2020-03-24
AU2013268303B2 (en) 2017-01-05
TW201408627A (zh) 2014-03-01
WO2013180271A1 (ja) 2013-12-05
IN2014DN10538A (el) 2015-08-21
DK2857385T3 (en) 2017-09-11
MX2014014642A (es) 2015-02-12
EP2857385A1 (en) 2015-04-08
KR20150016248A (ko) 2015-02-11
PH12014502670B1 (en) 2015-02-02
CA2875080A1 (en) 2013-12-05
JP5979230B2 (ja) 2016-08-24
LT2857385T (lt) 2017-10-25
NO2857385T3 (el) 2017-12-30
BR112014029478B1 (pt) 2023-01-17
RS56328B1 (sr) 2017-12-29
SI2857385T1 (sl) 2017-10-30
EP2857385A4 (en) 2015-11-11
PT2857385T (pt) 2017-11-08
TWI602801B (zh) 2017-10-21
HRP20171373T1 (hr) 2017-11-03
US20150141669A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CY1119646T1 (el) Προφαρμακο αμινοξεος που περιεχει φθοριο
CY1118021T1 (el) Παραγωγο αζολιου
CL2018000036A1 (es) Derivados etinilo
CY1124574T1 (el) Προφαρμακο παραγωγου αμινοξεος
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
CY1115826T1 (el) Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
AR093042A1 (es) Derivados de etinilo
CY1116518T1 (el) Παραγωγο 1,2,4-τριαζολονης
PH12015502692B1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
CR20190014A (es) Derivados etinilo
PH12015500496A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
GB201115937D0 (en) 18F-labelled compounds for use as positron emission imaging agents
TH147941A (th) โพรดรักของกรดอะมิโนที่มีฟลูออรีน
CY1122588T1 (el) 3 αλφα-αιθυνυλ, 3 βητα-υδροξυ 5-αλφα-πρεγναν-20-οξιμη για χρηση στη θεραπεια διαταραχων του κνς
DE602008005014D1 (de) Prolinamidtetrazolderivate als nk3-rezeptorantagonisten
TH103570A (th) 4-(แอริล-x-ฟีนิล)-1h-ไพริดิน-2-โอนซึ่งถูกแทนที่ที่ตำแหน่ง 1,3